• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Lapatinib Ditosylate Monohydrate

Lapatinib Ditosylate Monohydrate

Product ID L0360
Cas No. 388082-78-8
Purity ≥99%
Product Unit SizeCostQuantityStock
5 mg $47.30 In stock
10 mg $68.30 In stock
25 mg $89.30 In stock
100 mg $210.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Lapatinib is an inhibitor of EGFR/HER2 (ErbB2) that is currently in clinical trials as a co-administered treatment with other chemotherapeutics. Lapatinib exhibits anticancer chemotherapeutic benefit, inducing apoptosis in breast cancer cells. This compound also downregulates expression of thymidylate synthase in vitro.

Product Info

Cas No.

388082-78-8

Purity

≥99%

Formula

C26H26ClFN4O4S • 2C7H8O3S • H2O

Formula Wt.

925.46

IUPAC Name

N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2- methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine;4- methylbenzenesulfonic acid

Melting Point

236-259°C

Solubility

Slightly in DMSO

Appearance

Pale yellow to yellow powder

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

L0360 MSDS PDF

Info Sheet

L0360 Info Sheet PDF

References

Janni W, Sarosiek T, Karaszewska B, et al. A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2014 Jan 9. [Epub ahead of print]. PMID: 24402830.

Kostyal D, Welt RS, Danko J, et al. Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling. Med Oncol. 2012 Sep;29(3):1486-94. PMID: 21769502.

Kim HP, Yoon YK, Kim JW, et al. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One. 2009 Jun 16;4(6):e5933. PMID: 19529774.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • J889290

    JWH 133

    Cannabinoid receptor 2 selective agonist.

    ≥95%
  • D5753

    Donepezil Hydrochloride

    GSK3 and AChE inhibitor, potential σ1 agonist....

    ≥98%
  • M403007

    MK-3697

    Orexin 2 receptor antagonist

    ≥98%
  • K9200

    KX1-004

    Indole; Src inhibitor.

    ≥98%
  • Z161022

    α-Zearalanol

    Mycotoxin that has structural similarity to est...

    ≥98%
  • A5283

    [Sar1]-Angiotensin II

    Peptide, derivative of AT II, involved in vasoc...

    ≥95%
  • P8118

    Puerarin

    Isoflavone daidzein derivative found in Puerari...

    ≥96%
  • T5769

    Toremifene Base

    SERM, androgen modulator.

    ≥98%
  • C0171

    Carboplatin

    Pt-based DNA cross-linker.

    ≥99%
  • N5072

    NMS-1286937

    PLK1 inhibitor.

    ≥98%
  • T2833

    1-Thio-β-D-glucose Tetraacetate

    Imaging agent; Maillard reaction inhibitor.

    ≥98%
  • A9812

    AZD-1480

    JAK1/2 inhibitor.

    ≥98%
  • O4556

    Olomoucine

    Purine derivative; CDK inhibitor.

    ≥98%
  • D1792

    Dextromethorphan Hydrobromide Hydrate

    σ1/2and μ/κ/δ-OR agonist, α3β4/α4β2/α7...

    ≥98%
  • F4480

    5-Fluorouracil

    Pyrimidine analog; inhibits thymidylate synthas...

    ≥98%
  • O7992

    OTX-015

    BRD2/3/4 inhibitor.

    ≥98%
  • B9700

    BYL719

    p110α PI3K inhibitor.

    ≥99%, ≥99%ee
  • C2540

    CGK 733

    ATM and ATR inhibitor.

    ≥98%
  • C0261

    Captopril

    ACE inhibitor.

    ≥98%
  • V3252

    Vinorelbine Ditartrate

    Semi-synthetic vinca alkaloid from Catharanthus...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only